

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/55		A2	(11) International Publication Number: WO 96/24373 (43) International Publication Date: 15 August 1996 (15.08.96)
(21) International Application Number: PCT/US96/01969 (22) International Filing Date: 9 February 1996 (09.02.96) (30) Priority Data: 08/386,852 10 February 1995 (10.02.95) US			(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(60) Parent Application or Grant (63) Related by Continuation US Filed on 08/386,852 (CIP) 10 February 1995 (10.02.95)			Published <i>Without international search report and to be republished upon receipt of that report.</i>
(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): MACLAUGHLAN, Todd, E. [CA/US]; 34128 Sulkey Drive, Grayslake, IL 60030 (US). PEREZ, Alfonso, T. [US/US]; 1286 Cascade Court, Lake Forest, IL 60045 (US).			
(74) Agents: KEANE, J., Timothy et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).			
(54) Title: COMBINATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND SIDE-EFFECT-REDUCED AMOUNT OF ALDOSTERONE ANTAGONIST			
(57) Abstract <p>Combinations of an ACE inhibitor and an aldosterone receptor antagonist are described for use in treatment of circulatory disorders. Of particular interest are therapies using captopril or enalapril co-administered with a low-dose of spironolactone. This co-therapy would be particularly useful to treat or prevent the progression of congestive heart failure while avoiding or reducing aldosterone-antagonist-induced side effects such as hyperkalemia.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

COMBINATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND
SIDE-EFFECT-REDUCED AMOUNT OF ALDOSTERONE ANTAGONIST

5

Field of the Invention

Combinations of an angiotensin converting enzyme inhibitor and an aldosterone receptor antagonist are described for use in treatment of circulatory disorders, including cardiovascular diseases such as heart failure, hypertension and congestive heart failure. Of particular interest are therapies using a spirolactone-type aldosterone receptor antagonist compound in combination with an angiotensin converting enzyme inhibitor, using a side-effect-reduced amount of the aldosterone receptor antagonist.

Background of the Invention

20

Myocardial (or cardiac) failure, that is, heart failure ("HF"), whether a consequence of previous myocardial infarction(s), heart disease associated with hypertension, or primary cardiomyopathy, is a major health problem of worldwide proportions. The incidence of symptomatic heart failure has risen steadily over the past several decades.

In clinical terms, decompensated cardiac failure consists of a constellation of signs and symptoms that arise from congested organs and hypoperfused tissues to form congestive heart failure (CHF) syndrome. Congestion is caused largely by increased venous pressure and by inadequate sodium (Na^+) excretion, relative to dietary Na^+ intake, and is importantly related to circulating levels of aldosterone (ALDO). An abnormal retention of Na^+ occurs via tubular epithelial cells throughout the nephron,

including the later portion of the distal tubule and cortical collecting ducts, where ALDO receptor sites are present.

5 ALDO is the body's most potent mineralocorticoid hormone. As connoted by the term mineralocorticoid, this steroid hormone has mineral-regulating activity. It promotes Na⁺ reabsorption not only in the kidney, but also from the lower gastrointestinal tract and salivary and
10 sweat glands, each of which represents classic ALDO-responsive tissues. ALDO regulates Na⁺ and water resorption at the expense of potassium (K⁺) and magnesium (Mg²⁺) excretion.

15 ALDO can also provoke responses in non-epithelial cells. Elicited by a chronic elevation in plasma ALDO level that is inappropriate relative to dietary Na⁺ intake, these responses can have adverse consequences on the structure of the cardiovascular system. Hence, ALDO
20 can contribute to the progressive nature of myocardial failure for multiple reasons.

Multiple factors regulate ALDO synthesis and metabolism, many of which are operative in the patient with
25 myocardial failure. These include renin as well as non-renin-dependent factors (such as K⁺, ACTH) that promote ALDO synthesis. Hepatic blood flow, by regulating the clearance of circulating ALDO, helps determine ALDO plasma concentration, an important factor in heart failure
30 characterized by reduction in cardiac output and hepatic blood flow.

The renin-angiotensin-aldosterone system ("RAAS") is one of the hormonal mechanisms involved in regulating
35 pressure/volume homeostasis and also in the development of hypertension, a precursor condition implicated in the progression of more serious cardiovascular diseases such as congestive heart failure. Activation of the renin-

angiotensin-aldosterone system begins with secretion of the enzyme renin from the juxtaglomerular cells in the kidney. The enzyme renin acts on a naturally-occurring substrate, angiotensinogen, to release a decapeptide, Angiotensin I.

- 5 This decapeptide is cleaved by angiotensin converting enzyme ("ACE") to provide an octapeptide, Angiotensin II, the primary active species of this system. This octapeptide, angiotensin II, is a potent vasoconstrictor and also produces other physiological effects such as
10 stimulating aldosterone secretion, promoting sodium and fluid retention, inhibiting renin secretion, increasing sympathetic nervous system activity, stimulating vasopressin secretion, causing positive cardiac inotropic effect and modulating other hormonal systems.

15

- Emphasis has been placed on minimizing hyperaldosteronism as a basis for optimizing patient treatment. This includes the importance of ALDO-receptor antagonism both in patients treated with conventional
20 diuretic programs and in patients treated with angiotensin-converting enzyme (ACE) inhibitors, who are often constrained to small doses of ACE inhibitor because of orthostatic hypotension. Such patients may demonstrate a recurrence of heart failure symptoms likely related to
25 elevations in plasma ALDO levels.

- Many aldosterone receptor blocking drugs and their effects in humans are known. For example, spironolactone is a drug which acts at the mineralocorticoid receptor
30 level by competitively inhibiting aldosterone binding. This steroidal compound has been used for blocking aldosterone-dependent sodium transport in the distal tubule of the kidney in order to reduce edema and to treat essential hypertension and primary hyperaldosteronism [F. Mantero et al, Clin. Sci. Mol. Med., 45 (Suppl 1), 219s-
35 224s (1973)]. Spironolactone is also used commonly in the treatment of other hyperaldosterone-related diseases such

as liver cirrhosis and congestive heart failure [F.J. Saunders et al, Aldactone; Spironolactone: A Comprehensive Review, Searle, New York (1978)]. Progressively-increasing doses of spironolactone from 1 mg to 400 mg per day [i.e., 5 1 mg/day, 5 mg/day, 20 mg/day] was administered to a spironolactone-intolerant patient to treat cirrhosis-related ascites [P.A. Greenberger et al, N. Eng. Reg. Allergy Proc., 7(4), 343-345 (Jul-Aug, 1986)]. It has been recognized that development of myocardial fibrosis is 10 sensitive to circulating levels of both Angiotensin II and aldosterone, and that the aldosterone antagonist spironolactone prevents myocardial fibrosis in animal models, thereby linking aldosterone to excessive collagen deposition [D. Klug et al, Am. J. Cardiol., 71(3), 46A-54A (1993)]. Spironolactone has been shown to prevent fibrosis 15 in animal models irrespective of the development of left ventricular hypertrophy and the presence of hypertension [C.G. Brilla et al, J. Mol. Cell. Cardiol., 25(5), 563-575 (1993)]. Spironolactone at a dosage ranging from 25 mg to 20 100 mg daily is used to treat diuretic-induced hypokalemia, when orally-administered potassium supplements or other potassium-sparing regimens are considered inappropriate [Physicians' Desk Reference, 46th Edn., p. 2153, Medical Economics Company Inc., Montvale, N.J. (1992)].

25

Previous studies have shown that inhibiting ACE inhibits the renin-angiotensin system by substantially complete blockade of the formation of Angiotensin II. Many ACE inhibitors have been used clinically to control 30 hypertension. While ACE inhibitors may effectively control hypertension, side effects are common including chronic cough, skin rash, loss of taste sense, proteinuria and neutropenia.

35

Moreover, although ACE inhibitors effectively block the formation of Angiotensin II, aldosterone levels are not well controlled in certain patients having

cardiovascular diseases. For example, despite continued ACE inhibition in hypertensive patients receiving captopril, there has been observed a gradual return of plasma aldosterone to baseline levels [J. Staessen et al, 5 J. Endocrinol., 91, 457-465 (1981)]. A similar effect has been observed for patients with myocardial infarction receiving zofenopril [C. Borghi et al, J. Clin. Pharmacol., 33, 40-45 (1993)]. This phenomenon has been termed "aldosterone escape".

10

Combinations of an aldosterone antagonist and an ACE inhibitor have been investigated for treatment of heart failure. It is known that mortality is higher in patients with elevated levels of plasma aldosterone and that 15 aldosterone levels increase as CHF progresses from RAAS activation. Routine use of a diuretic may further elevate aldosterone levels. ACE inhibitors consistently inhibit angiotensin II production but exert only a mild and transient antialdosterone effect.

20

Combining an ACE inhibitor and spironolactone has been suggested to provide substantial inhibition of the entire RAAS. For example, a combination of enalapril and a 25 mg daily dose of spironolactone has been administered to 25 ambulatory patients with monitoring of blood pressure [P. Poncelet et al, Am. J. Cardiol., 65(2), 33K-35K (1990)]. In a 90-patient study, a combination of spironolactone at a dose in a range from 50mg/day to 100 mg/day (average 73 mg/day) and captopril was administered and found effective 30 to control refractory CHF without serious incidents of hyperkalemia [U. Dahlstrom et al, Am. J. Cardiol., 71, 29A-33A (21 Jan 1993)]. Spironolactone dosage at 100 mg/day coadministered with an ACE inhibitor was reported to be highly effective in 13 of 16 patients afflicted with 35 congestive heart failure, with a 25 mg/day to 50 mg/day spironolactone maintenance dosage given at trial completion to compensated patients being treated with an ACE inhibitor

and loop diuretic [A.A. van Vliet et al, Am. J. Cardiol., 71, 21A-28A (21 Jan 1993)]. Clinical improvements have been reported for patients receiving a co-therapy of spironolactone and the ACE inhibitor enalapril, although 5 this report mentions that controlled trials are needed to determine the lowest effective doses and to identify which patients would benefit most from combined therapy [F. Zannad, Am. J. Cardiol., 71(3), 34A-39A (1993)].

10

Summary of Drawing Figures

Fig. 1 shows urinary aldosterone levels at different rates of spironolactone administration (12.5 mg, 25 mg, 50mg, 75mg), as compared to placebo, co-administered 15 with stable doses of ACE inhibitor and loop diuretic.

Fig. 2 shows plasma renin activity at different rates of spironolactone administration (12.5 mg, 25 mg, 50mg, 75mg), as compared to placebo, co-administered 20 with stable doses of ACE inhibitor and loop diuretic.

Fig. 3 shows N-Terminal ANF levels at different rates of spironolactone administration (12.5 mg, 25mg, 50mg, 75mg), as compared to placebo, co-administered 25 with stable doses of ACE inhibitor and loop diuretic.

Fig. 4 shows changes in supine blood pressure at different rates of spironolactone administration (12.5 mg, 25mg, 50mg, 75mg), as compared to placebo, co-administered 30 with stable doses of ACE inhibitor and loop diuretic.

Fig. 5 shows changes in supine heart rate at different rates of spironolactone administration (12.5 mg, 25mg, 50mg, 75mg), as compared to placebo co-administered 35 with stable doses of ACE inhibitor and loop diuretic.

Description of the Invention

Treatment or prevention of circulatory disorders,
5 including cardiovascular disorders such as heart failure, hypertension and congestive heart failure, is provided by a combination therapy comprising a therapeutically-effective amount of an angiotensin converting enzyme ("ACE") inhibitor along with a therapeutically-effective amount of
10 a spirolactone-type aldosterone receptor antagonist. Preferably, the spirolactone-type aldosterone receptor antagonist is administered in the combination therapy at a low dose, that is, at a dose lower than has been conventionally used in clinical situations.

15

The combination therapy of the invention would be useful, for example, to prevent or retard, in a subject, the development of congestive heart failure which typically arises from essential hypertension or from heart conditions
20 following myocardial infarct. Such subject would not typically be suffering from an edematous condition and thus would not gain benefit from treatment with conventional diuretic therapy as with loop diuretics which can alter electrolyte balance and cause hypokalemic or hypomagnesia
25 conditions.

The phrase "angiotensin converting enzyme inhibitor" ("ACE inhibitor") is intended to embrace an agent or compound, or a combination of two or more agents or compounds, having the ability to block, partially or completely, the rapid enzymatic conversion of the physiologically inactive decapeptide form of angiotensin ("Angiotensin I") to the vasoconstrictive octapeptide form of angiotensin ("Angiotensin II"). Blocking the formation of Angiotensin II can quickly affect the regulation of fluid and electrolyte balance, blood pressure and blood volume, by removing the primary actions of Angiotensin II.

Included in these primary actions of Angiotensin II are stimulation of the synthesis and secretion of aldosterone by the adrenal cortex and raising blood pressure by direct constriction of the smooth muscle of the arterioles.

5

The phrase "aldosterone receptor antagonist" embraces an agent or compound, or a combination of two or more of such agents or compounds, which agent or compound binds to the aldosterone receptor as a competitive inhibitor of the action of aldosterone itself at an aldosterone receptor site, such as typically found in the renal tubules, so as to modulate the receptor-mediated activity of aldosterone. Typical of such aldosterone receptor antagonists are spirolactone-type compounds. The term "spirolactone-type" is intended to characterize a steroidal structure comprising a lactone moiety attached to a steroid nucleus, typically at the steroid "D" ring, through a spiro bond configuration.

20

The phrase "combination therapy" (or "co-therapy"), in defining use of an ACE inhibitor agent and an aldosterone receptor antagonist agent, is intended to embrace administration of each agent in a sequential manner in a regimen that will provide beneficial effects of the drug combination, and is intended as well to embrace co-administration of these agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of these active agents or in multiple, separate capsules for each agent.

25

The phrase "therapeutically-effective" is intended to qualify the amount of each agent for use in the combination therapy which will achieve the goal of improvement in cardiac sufficiency by reducing or preventing, for example, the progression of congestive heart failure, while avoiding adverse side effects typically associated with each agent.

The phrase "low-dose amount", in characterizing a therapeutically-effective amount of the aldosterone receptor antagonist agent in the combination therapy, is intended to define a quantity of such agent, or a range of quantity of such agent, that is capable of improving cardiac sufficiency while reducing or avoiding one or more aldosterone-antagonist-induced side effects, such as hyperkalemia. A dosage of spironolactone which would accomplish the therapic goal of favorably enhancing cardiac sufficiency, while reducing or avoiding side effects, would be a dosage that substantially avoids inducing diuresis, that is, a substantially non-diuresis-effective dosage.

A preferred combination therapy would consist essentially of two active agents, namely, an ACE inhibitor agent and aldosterone receptor antagonist agent. The agents would be used in combination in a weight ratio range from about 0.5-to-one to about twenty-to-one of the angiotensin converting enzyme agent to the aldosterone receptor antagonist agent. A preferred range of these two agents (ACE inhibitor-to-ALDO antagonist) would be from about one-to-one to about fifteen-to-one, while a more preferred range would be from about one-to-one to about five-to-one, depending ultimately on the selection of the ACE inhibitor and ALDO antagonist.

Examples of ACE inhibitors which may be used in the combination therapy are shown in the following four categories.

A first group of ACE inhibitors consists of the following compounds: AB-103, ancovenin, benazeprilat, BRL-36378, BW-A575C, CGS-13928C, CL-242817, CV-5975, Equaten, EU-4865, EU-4867, EU-5476, foroxymithine, FPL 66564, FR-900456, Hoe-065, I5B2, indolapril, ketomethylureas, KRI-1177, KRI-1230, L-681176, libenzapril, MCD, MDL-27088, MDL-

27467A, moveltipril, MS-41, nicotianamine, pentopril,
phenacein, pivopril, rentiapril, RG-5975, RG-6134, RG-6207,
RGH-0399, ROO-911, RS-10085-197, RS-2039, RS 5139,
RS 86127, RU-44403, S-8308, SA-291, spiraprilat, SQ-26900,
5 SQ-28084, SQ-28370, SQ-28940, SQ-31440, Synecor, utibapril,
WF-10129, Wy-44221, Wy-44655, Y-23785, Yissum P-0154,
zabicipril and.

A second group of ACE inhibitors of interest
10 consists of the following compounds: Asahi Brewery
AB-47, alatriopril, BMS 182657, Asahi Chemical C-111, Asahi
Chemical C-112, Dainippon DU-1777, mixanpril, Prentyl,
zofenoprilat and 1-(-(1-carboxy-6-(4-piperidinyl)hexyl)
amino)-1-oxopropyl octahydro-1H-indole-2-carboxylic acid.


15 A third group of ACE inhibitors of greater
interest consists of the following compounds: Bioproject
BP1.137, Chiesi CHF 1514, Fisons FPL-66564, idrapril,
Marion Merrell Dow MDL-100240, perindoprilat and Servier S-
20 5590.

A fourth group of ACE inhibitors of highest
interest consists of the following compounds: alacepril,
benazepril, captopril, cilazapril, delapril, enalapril,
25 enalaprilat, fosinopril, fosinoprilat, imidapril,
lisinopril, perindopril, quinapril, ramipril, saralasin
acetate, temocapril, trandolapril, ceranapril, moexipril,
quinaprilat and spirapril.


30 Many of these ACE inhibitors are commercially
available, especially those listed in the fourth group,
above. For example, a highly preferred ACE inhibitor,
captopril, is sold by E.R. Squibb & Sons, Inc., Princeton,
N.J., now part of Bristol-Myers-Squibb, under the trademark
35 "CAPOTEN", in tablet dosage form at doses of 12.5 mg, 50 mg
and 100 mg per tablet. Enalapril or Enalapril Maleate, and
Lisinopril are two more highly preferred ACE inhibitors sold

by Merck & Co, West Point, Pa. Enalapril is sold under the trademark "VASOTEC" in tablet dosage form at doses of 2.5 mg, 5 mg, 10 mg and 20 mg per tablet. Lisinopril is sold under the trademark "PRINIVIL" in tablet dosage form at 5 doses of 5 mg, 10 mg, 20 mg and 40 mg per tablet.

A family of spirolactone-type compounds of interest is defined by Formula I



wherein $\text{---C}_6\text{---C}_7\text{---}$ is



10

wherein R is lower alkyl of up to 5 carbon atoms,
and

wherein $\text{---C}_{15}\text{---C}_{16}\text{---}$ is



15


Lower alkyl residues include branched and unbranched groups, preferably methyl, ethyl and n-propyl.

20 Specific compounds of interest within Formula I are the following:

7 α -Acetylthio-3-oxo-4,15-androstadiene-[17(β -1')-spiro-5']perhydrofuran-2'-one;
3-Oxo-7 α -propionylthio-4,15-androstadiene-[17((β -1')-

- spiro-5']perhydrofuran-2'-one;
- 6 β ,7 β -Methylene-3-oxo4,15-androstadiene-[17((β -1')-spiro-5']perhydrofuran-2'-one;
- 15 α ,16 α -Methylene-3-oxo-4,7 α -propionylthio-4-androstene[17(β -1')-spiro-5']perhydrofuran-2'-one;
- 6 β ,7 β ,15 α ,16 α -Dimethylene-3-oxo-4-androstene-[17(β -1')-spiro-5']perhydrofuran-2'-one;
- 7 α -Acetylthio-15 β ,16 β -Methylene-3-oxo-4-androstene-[17(β -1')-spiro-5']perhydrofuran-2'-one;
- 15 β ,16 β -Methylene-3-oxo-7 β -propionylthio-4-androstene-[17(β -1')-spiro-5']perhydrofuran-2'-one; and
- 6 β ,7 β ,15 β ,16 β -Dimethylene-3-oxo-4-androstene-[17(β -1')-spiro-5']perhydrofuran-2'-one.
- 15 Methods to make compounds of Formula I are described in U.S. Patent No. 4,129,564 to Wiechart et al issued on 12 December 1978.

20 A second family of spirolactone-type compounds of interest is defined by Formula II:



wherein R¹ is C₁₋₃-alkyl or C₁₋₃ acyl and R² is H or
25 C₁₋₃-alkyl.


Specific compounds of interest within Formula II are the following:

- 1 α -Acetylthio-15 β ,16 β -methylene-7 α -methylthio-3-oxo-
 5 17 α -pregn-4-ene-21,17-carbolactone; and
 15 β ,16 β -Methylene-1 α ,7 α -dimethylthio-3-oxo-17 α -pregn-
 4-ene-21,17-carbolactone.

Methods to make the compounds of Formula II are described
 10 in U.S. Patent No. 4,789,668 to Nickisch et al which issued
 6 December 1988.

A third family of spirolactone-type compounds of interest is defined by a structure of Formula III:

15




wherein R is lower alkyl, with preferred lower alkyl groups being methyl, ethyl, propyl and butyl. Specific compounds
 20 of interest include:

3 β ,21-dihydroxy-17 α -pregna-5,15-diene-17-carboxylic acid γ -lactone;


3 β ,21-dihydroxy-17 α -pregna-5,15-diene-17-carboxylic acid 3-acetate;

- 3 β ,21-dihydroxy-17 α -pregn-5-ene-17-carboxylic acid γ -lactone;*
- 3 β ,21-dihydroxy-17 α -pregn-5-ene-17-carboxylic acid γ -lactone 3-acetate;*
- 5 *21-hydroxy-3-oxo-17 α -pregn-4-ene-17-carboxylic acid γ -lactone;*
- 21-hydroxy-3-oxo-17 α -pregna-4,6-diene-17-*
- carboxylic acid γ -lactone;*
- 21-hydroxy-3-oxo-17 α -pregna-1,4-diene-17-*
- 10 *carboxylic acid γ -lactone;*
- 7 α -acylthio-21-hydroxy-3-oxo-17 α -pregn-4-ene-17-*
- carboxylic acid γ -lactones; and*
- 7 α -acetylthio-21-hydroxy-3-oxo-17 α -pregn-4-ene-*
- 17-carboxylic acid γ -lactone.*
- 15
- Methods to make the compounds of Formula III are described in U.S. Patent No. 3,257,390 to Patchett which issued 21 June 1966.
- 20 A fourth family of compounds of interest is represented by Formula IV:



wherein E' is selected from the group consisting of ethylene, vinylene and (lower alkanoyl)thioethylene radicals, E" is selected from the group consisting of ethylene, vinylene, (lower alkanoyl)thioethylene and (lower 5 alkanoyl)thiopropylene radicals; R is a methyl radical except when E' and E" are ethylene and (lower alkanoyl) thioethylene radicals, respectively, in which case R is selected from the group consisting of hydrogen and methyl radicals; and the selection of E' and E" is such that at 10 least one (lower alkanoyl)thio radical is present.

A preferred family of compounds within Formula IV is represented by Formula V:




15

A more preferred compound of Formula V is 1-acetylthio-17 α -(2-carboxyethyl)-17 β -hydroxy-androst-4-en-3-one lactone.

20

Another preferred family of compounds within Formula IV is represented by Formula VI:



5


More preferred compounds within Formula VI include the following:

- 10 7α -acetylthio- 17α -(2-carboxyethyl)- 17β -hydroxy-androst-4-en-3-one lactone;
- 7β -acetylthio- 17α -(2-carboxyethyl)- 17β -hydroxy-androst-4-en-3-one lactone;
- $1\alpha, 7\alpha$ -diacetylthio- 17α -(2-carboxyethyl)- 17β -hydroxy-androsta-4,6-dien-3-one lactone;
- 15 7α -acetylthio- 17α -(2-carboxyethyl)- 17β -hydroxy-androsta-1,4-dien-3-one lactone;
- 7α -acetylthio- 17α -(2-carboxyethyl)- 17β -hydroxy-19-norandrost-4-en-3-one lactone; and
- 7α -acetylthio- 17α -(2-carboxyethyl)- 17β -hydroxy-
- 20 6α -methylandrost-4-en-3-one lactone;

In Formula IV-VI, the term "alkyl" is intended to embrace linear and branched alkyl radicals containing one to about eight carbons. The term "(lower alkanoyl)thio" embraces radicals of the formula lower alkyl $\text{---} \overset{\text{O}}{\underset{\text{||}}{\text{C}}} \text{---} \text{S}$.

Of particular interest is the compound spironolactone having the following structure and formal name:

5



"spironolactone": 17-hydroxy-7α-mercaptopro-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone acetate

10 Methods to make compounds of Formula IV-VI are described in U.S. Patent No. 3,013,012 to Cella et al which issued 12 December 1961. Spironolactone is sold by G.D. Searle & Co., Skokie, Illinois, under the trademark "ALDACTONE", in tablet dosage form at doses of 25 mg, 50 mg
15 and 100 mg per tablet.

20 A diuretic agent may be used with the combination of ACE inhibitor and aldosterone receptor antagonist. Such diuretic agent may be selected from several known classes, such as thiazides and related sulfonamides, potassium-sparing diuretics, loop diuretics and organic mercurial diuretics.

25 Examples of thiazides are bendroflumethiazide, benzthiazide, chlorothiazide, cyclothiazide, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, polythiazide and trichlormethiazide.

30 Examples of related sulfonamides are chlorthalidone, quinethazone and metolazone.

An example of a non-thiazide sulfonamide diuretic is metolazone.

Examples of potassium-sparing diuretics are
5 triameterene and amiloride.

Examples of loop diuretics, i.e., diuretics acting in the ascending limb of the loop of Henle of the kidney, are furosemide and ethynacrylic acid.

10 Examples of organic mercurial diuretics are mercaptomerin sodium, merethoxylline procaine and mersalyl with theophylline.

15 Biological Evaluation

Human Clinical Trials

20 A combination therapy of ACE inhibitor and spironolactone was evaluated in humans as described in the following clinical trials.

Patients: Two-hundred fourteen (214) patients with
25 symptomatic heart failure had an ejection fraction $\leq 35\%$, a history of New York Heart Association (NYHA) functional classification III-IV six months prior to enrollment, and current classification II-IV were randomized among five treatment groups. Patients were assigned to receive either
30 spironolactone 12.5 mg (41 patients), 25 mg (45 patients), 50 mg (47 patients), 75 mg (41 patients), or placebo (40 patients) once a day for 12 weeks. Two patients that were randomized failed to take the study medication and were excluded from the analysis. All patients were taking a
35 stable dose of ACE inhibitor, loop diuretic, and optional digitalis for 30 days prior to the first dose of study medication. Potassium supplement therapy that was stable

for 14 days prior to the first dose of study medication was also allowed. Informed consent was obtained from all patients, and the protocol was approved by each ethical committee. At enrollment all patients had normal serum 5 potassium values (<5.5 mmol/L) and creatinine values of ≤2.0 mg/dL or ≤180 mmol/L. Patients were excluded from enrollment if they: (1) were diagnosed with either an acute life-threatening disease (included patients with automatic implantable cardioverter/ defibrillator),
10 valvular disease, unstable angina, insulin-dependent diabetes, cancer (without a reoccurrence within the last five years), or primary hepatic failure; (2) were on a waiting list for a heart transplant or experienced a myocardial infarction 30 days prior to the first dose of
15 study medication; (3) had laboratory values for hematology or biochemistry considered abnormal and clinically significant prior to the first dose of study medication; (4) received a potassium spacing diuretic within 30 days prior to the first dose of study medication.; (5) were
20 receiving, on a regular basis, either non-steroidal anti-inflammatory drugs or aspirin >325 mg/day, steroids, dopamine agonists or antagonists, insulin or heparin; (6) were on any investigational medication within 30 days of
the first dose of medication.
25

Study Design: This was a multinational, double-blind, randomized, parallel group study.

Laboratory Measurements: The following information was
30 obtained from each patient at baseline:

1. Concurrent medication within the past 30 days.
2. 12-lead ECG
3. Cardiac assessments that included blood pressure, pulse,
35 sodium retention score (general assessment of a patient's edematous state was derived from the summation

of scores obtained from Table I), NYHA classification,
and

4. Signs and symptoms within the past 30 days.

5

Table I
Sodium Retention Score

	<u>Parameters</u>	<u>Grade</u>	<u>Assessment</u>
10	Rales	0	Absent
		1	In lower 1/3 of lungs
		2	In lower 2/3 of lungs
		3	In all lung fields
15	Peripheral Pitting Edema	0	Absent
		1	Trace
		2	Limited to ankles
		3	Not limited to ankles
		4	Anasarca
20	Weight Change	-1	Decreased
		0	Unchanged
		1	Increased
25	Hepatomegaly	0	Absent
		1	Present
30	S3 Gallop	0	Absent
		1	Present
35	Increased Jugular Venous Pressure	0	Absent
		1	Present

35 The following laboratory values were obtained at the pretreatment visit:

- Hematology: White blood cell count (WBC), hematocrit, hemoglobin, platelet count.
- 40 Biochemistry: Creatinine, potassium, AST, SGOT, urinary sodium/potassium ratio, bicarbonate, calcium, chloride, creatinine, creatinine clearance, magnesium, glucose, urea, uric acid.
- 45

Neurohormones: Plasma renin activity, pro-atrial natriuretic factor, urinary aldosterone.

Blood and urine samples were centrally analyzed at SciCor Laboratories. Laboratory values for urinary aldosterone and renin levels were done at the Ohio State University Laboratory in Columbus, Ohio. Pro-atrial natriuretic factor samples were evaluated at the University of Oslo Laboratory in Oslo, Norway. Patients were evaluated 9 days after beginning study medication. Documented changes in concurrent medications, signs and symptoms and drug compliance were recorded. These procedures were repeated at Week 4 and Week 8 visits. Patient information and procedures on the final visit (Week 12) was identical to the pre-treatment visit.

Statistical Analysis: Analysis of cardiac assessment changes in patient therapy and vital signs were performed for both the Intent-to-Treat (ITT) and evaluable patient groups. Analysis of demographic variables, adverse events and clinical laboratory values were performed in the ITT group. For each efficacy variable, results of each visit were examined separately. An appropriate trend test was used to test for overall dose-response. Pair-wise comparisons were made for each active dose to placebo. Significant levels for pair-wise comparisons were adjusted using the Hochberg-Bonferroni method to maintain the overall Type I error rate. All statistical methods were two-sided.

30

Recruitment: Two-hundred and fourteen patients were recruited from 22 study sites in eleven countries.

35 **Patient Characteristics:** Patient demographic, vital signs, and cardiac status at baseline are summarized in Table II.

TABLE II
Patient Demographics

		Demographic	spironolactone 12.5 mg/d	spironolactone 25 mg/d	spironolactone 50 mg/d	spironolactone 75 mg/d	Placebo	P-value
5	Demographic							
	Age (years)	63 ±12	61 ±9	62 ±13	62 ±13	61 ±12	N.S.	
	Caucasian/other (%)	93/7	98/2	93/7	88/12	97/3	N.S.	
	Male/female (%)	78/22	82/18	74/26	88/12	83/18	N.S.	
10	Vital Signs							
	Weight (kg)	74	75	73	78	73	N.S.	
	Blood pressure (mmHg)							
	Systolic	121	120	121	125	121	N.S.	
	Diastolic	76	76	75	81	74	N.S.	
	Pulse (bpm)	76	74	76	74	71	N.S.	
15	Cardiac Status							
	NYHA (%)							
	II	63	60	43	49	38		
	III	34	38	55	49	60		
	IV	2	2	2	2	2	N.S.	
	Sodium retention score							
	Mean value	1.54	1.62	1.64	1.61	1.78	N.S.	
20	ACE-I (Mean dose)							
	Captopril (mg)	57.3	57.5	69.7	59.4	65.4	N.S.	
	Enalapril (mg)	16.4	13.4	14.5	16.3	10.8	N.S.	
25	Loop Diuretic (Mean dose)							
	Furosemide (mg)	58.8	82.8	76.9	84.9	63.2	N.S.	
30	Digoxin (%)							
	Potassium supplement (%)	43.9	78.0	77.8	76.6	77.5	N.S.	
	(%)	35	37.8	37.8	34.0	30.0	N.S.	

Patients ranged in age from 26 to 83 years (mean = 60), 81% were male, 94% were Caucasian. At baseline 51% of the patients were NYHA Class II, 47% were Class III.

With respect to sodium retention score, a statistically significant dose response was seen at Day 9 with higher doses showing more reduction in sodium retention score ($p = 0.019$). However, this effect was not seen at later visits ($p > 0.20$). There was an improvement in NYHA Class placebo group and in all the spironolactone groups. Although a trend toward improvement in the spironolactone group was observed, the difference was not statistically significant.

Changes in Patient Therapy: The treatment groups did not differ significantly with respect to changes in dose of ACE inhibitor, digitalis or potassium supplements at any visit ($p \geq 0.11$). The treatment groups did differ significantly with respect to changes in loop diuretic therapy only at Week 8 ($p = 0.004$) in that more patients on the higher doses of spironolactone had decreases in the loop diuretic dose compared to the placebo group. This pattern was not observed at Week 12.

Changes in Vital Signs: Changes from baseline in vital signs at Week 12 are summarized in Table III.

TABLE III
Mean Change in Weight and Vital Signs from Baseline to Week 12

		Spironolactone 12.5 mg/d	Spironolactone 25 mg/d	Spironolactone 50 mg/d	Spironolactone 75 mg/d	Placebo	P-Value
10	Weight	0.59(3.00)	-0.16 (3.02)	0.62 (2.05)	-0.81 (2.70)	0.11 (2.46)	0.109
	Supine systolic BP	1.84(11.82)	-4.46(13.97)	-7.04(15.83)	-5.68(15.62)	0.22(13.45)	0.036
	Supine diastolic BP	-0.19(9.13)	-2.74 (9.57)	-5.11(11.11)	-5.91 (9.05)	1.78 (7.84)	0.014
15	Supine pulse (BPM)	-3.70(9.56)	-1.40(10.00)	-3.21(11.27)	-1.07(13.79)	1.42 (9.69)	0.422

At all visits the 25 mg, 50 mg, and 75 mg groups had decreases in mean systolic and diastolic blood pressure,
5 while the placebo group had increases in mean systolic and diastolic blood pressure (both standing and supine). Dose response with respect to standing and supine diastolic blood pressure was statistically significant for all visits ($p \leq 0.002$). Dose response with respect to standing and
10 supine blood pressure was statistically significant at Week 4, Week 8, and Week 12 ($p \leq 0.033$), but not at Day 9 ($p \geq 0.12$). No significant between-treatment differences in change from baseline in pulse were observed at any visit (p-values ≥ 0.136). A statistically significant dose
15 response with greater decreases in pulse in the supine position at higher doses was observed at Week 4 (p-value = 0.045). Spironolactone doses of 25 and 50 mg were also significantly different from placebo (p-values ≤ 0.043) (See Fig. 1). At Day 9 and Week 4 visits, there was a
20 statistically significant dose response with respect to changes from baseline in body weight in that patients in the 75 mg dose group experienced more weight loss than other patients. This dose response was not observed at later visits ($p \geq 0.062$).

25

Clinical Laboratory Values: Table IV contains details of the different clinical laboratory values that showed statistically significant treatment differences with respect to mean changes at Week 12 visit compared with
30 their respective baseline value.

TABLE IV
Week 12 Mean Change

		spironolactone 12.5 mg/d	spironolactone 25 mg/d	spironolactone 50 mg/d	spironolactone 75 mg/d	P- Placebo Value
5	Urinary aldosterone (nmol/D)	4.21	4.27	8.11	11.13	0.76 0.002
10	N-Terminal ANF (pmol/L)	-287.30	-294.60	-351.30	-370.60	54.50 0.022
	PRA (NgAng1/L/s)	9.90	9.33	13.18	10.23	0.50 0.002
15	Hematocrit (%)	0.00	-0.02	-0.02	-0.03	0.00 0.002
	Hemoglobin (mmol/L/Fe)	0.12	-0.20	-0.31	-0.46	0.00 0.005
	Potassium (mmol/L)	0.18	0.37	0.51	0.58	-0.10 0.001
20	Creatinine (umol/L)	6.83	9.30	14.06	21.90	-1.96 0.001
	Sodium (mmol/L)	-1.61	-1.85	-2.52	-3.37	-0.03 0.001

Urinary Aldosterone (See Fig. 1): Urinary aldosterone was determined only for baseline and the 12 week visit.

- 5 Urinary aldosterone excretion showed mean increases from baseline in all treatment groups ($P \leq 0.012$). Greater increases were seen at higher doses of spironolactone ($p = 0.002$). All pair-wise comparisons between active treatment and placebo were statistically significant ($p \leq 0.009$).

10

Plasma Renin Activity (PRA) (See Fig. 2): A statistically significant dose-response with respect to change from baseline in PRA was seen at Day 9, Week 4 and 15 Week 12 ($P \leq 0.001$) with higher doses of spironolactone associated with greater increases in PRA. PRA was not measured at Week 8.

N-Terminal Atrial Natriuretic Factor (ANF) (See

- 20 Fig. 3): All active treatments showed decreases from baseline at all treatment visits. Dose-response was statistically significant at Day 9 ($p = 0.048$), Week 4 ($p = 0.005$), and Week 12 ($p = 0.008$). ANF was not measured at Week 8. In comparisons the 50 mg dose group differed 25 significantly from placebo at Week 4 ($p = 0.009$) and Week 12 ($p = 0.006$), while the 75 mg dose group differed significantly from placebo at Week 12 only ($p = 0.007$).

Hematocrit and Hemoglobin: At Day 9 visit a

- 30 statistically significant mean value difference between placebo and the different active treatments was observed with lower values for the placebo group than the active treatments ($p < 0.001$). At Week 12 a reverse statistically significant difference was observed with lower levels for 35 the active treatment groups for hematocrit ($p = 0.002$) and hemoglobin (0.005).

Serum Potassium: A statistically significant dose-response with respect to change from baseline in serum potassium was seen at all treatment period visits ($p < 0.001$). Higher doses of spironolactone were associated 5 with larger increases in potassium. All doses of active treatment had significantly higher serum potassium levels relative to baseline than placebo ($p \leq 0.034$).

Incidence of Hyperkalemia

	Treatment: Placebo	Spironolactone 12.5 mg/d	Spironolactone 25 mg/d	Spironolactone 50 mg/d	Spironolactone 75 mg/d
	Patients (%) 2(5%)	2(5%)	6(13%)	9(20%)	10(24%)

15 Predictors of Hyperkalemia: Seven possible predictors of hyperkalemia (potassium ≥ 5.5 mmol/L) were included in a step-wise Cox regression analysis: randomized treatment (treated as a categorical variable), age, baseline NYHA 20 class, baseline serum potassium, baseline PRA, baseline creatinine, baseline urinary aldosterone, and type and dose of ACE-I. Besides the dose of spironolactone, the following predictors of hyperkalemia were statistically significant in the step-wise regression analysis: type of 25 ACE-I (captopril versus other), baseline serum creatinine, and baseline serum potassium. Results are summarized as follows:

	<u>Factor</u>	<u>p-value</u>	<u>Risk Ratio</u>
30	Captopril vs other ACE-I	0.013	0.318
	Serum Creatinine > normal	0.038	2.72
	Baseline Potassium > median	0.040	2.32

35 In this analysis, the risk ratio can be thought of as the probability that the patient with the risk factor will develop hyperkalemia, relative to the probability that a patient without the risk factor will develop it. (For example, patients on captopril are about one-third as likely 40 to develop hyperkalemia as a patient on another ACE-I.)

Risk ratios relative to placebo for the various doses of spironolactone are:

	<u>Dose</u>	<u>p-value</u>	<u>Risk Ratio</u>
5	Spironolactone 12.5 mg	0.98	1.02
	Spironolactone 25 mg	0.19	2.91
	Spironolactone 50 mg	0.034	5.32
	Spironolactone 75 mg	0.016	6.66

After adjusting for the above factors, other predictors included in the step-wise regression analysis were not significant (*p*-values ≥ 0.07). However, the following additional factor was significantly related to the development of hyperkalemia when considered apart from other predictors except the dose of spironolactone.

15

<u>Factor</u>	<u>p-value</u>	<u>Risk Ratio</u>
High ACE-I Dose	0.050	2.93

Serum Magnesium: Change from baseline in serum magnesium showed a statistically significant dose-response at Day 9 and Week 4 (*p* ≤ 0.048), with more patients in the placebo group showing decreases in serum magnesium. However, this effect was not seen at later visits (*p* ≥ 0.083).

25

Adverse Effects: Table V summarizes the twelve most common adverse events by different treatment groups. Only one symptom, hyperkalemia, showed a clear dose-response in term of incidence (*p* = 0.001).

30

Table V
 Incidence of Adverse Events
 Spironolactone Dose-Ranging Study
 Intent-to-Treat Cohort
 (Top Twelve Events)

		Treatment Group (Percentage of Patients)					
	Adverse Events	spironolactone 12.5 mg	spironolactone 25 mg	spironolactone 50 mg	spironolactone 75 mg	Placebo	Total
10	Dyspnea	22.0	15.6	26.1	24.4	30.0	23.5
15	Angina Pectoris	19.5	20.0	8.7	14.6	17.5	16.0
20	Dizziness	12.2	13.3	13.0	17.1	15.0	14.1
25	Fatigue	12.2	13.3	15.2	14.6	15.0	14.1
5	Nausea	2.4	17.8	6.5	19.5	12.5	11.7
10	Diarrhea	4.9	22.2	8.7	14.6	5.0	11.3
15	Abdominal Pain	7.3	8.9	13.0	7.3	17.5	10.8
20	Headache	9.8	2.2	15.2	7.3	20.0	10.8
25	Hyperkalemia	2.4	8.9	15.2	19.5	2.5	9.9
5	URT Infection	4.9	11.1	8.7	2.4	12.5	8.0
10	Arthralgia	4.9	4.4	8.7	4.9	7.5	6.1
15	Coughing	4.9	2.2	4.3	2.4	12.5	5.2

A breakdown of the hospitalizations is as follows:

	<u>Treatment</u>	<u>Placebo</u>	<u>12.5 mg</u>	<u>25 mg</u>	<u>50 mg</u>	<u>75 mg</u>	<u>P</u>
5	Patients (%)	5(12.5%)	3(7.3%)	3(6.6%)	13(27.6%)	6(14.6%)	N.S.

No deaths were reported during the drug treatment period. Three patients died within 30 days after the study was completed. These three patients were previously at the 50 mg dose.

Administration of the angiotensin converting enzyme inhibitor and the aldosterone receptor antagonist may take place sequentially in separate formulations, or may be accomplished by simultaneous administration in a single formulation or separate formulations. Administration may be accomplished by oral route, or by intravenous, intramuscular or subcutaneous injections. The formulation may be in the form of a bolus, or in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more pharmaceutically-acceptable carriers or diluents, or a binder such as gelatin or hydroxypropyl-methyl cellulose, together with one or more of a lubricant, preservative, surface-active or dispersing agent.

For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. The ACE inhibitor may be present in an amount from about 1 to 200 mg, preferably from about 2 to 150 mg, depending upon the specific ACE inhibitor selected. A suitable daily dose for a mammal may vary widely depending on the condition of the patient and other factors. The ALDO antagonist may be present in an amount of from about 1 to 400 mg, preferably from about 2 to 150 mg, depending upon the specific ALDO

antagonist compound selected and the specific disease state being targeted for the combination therapy.

For disease states which require prevention,
5 reduction or treatment of a cardiovascular disease state without incidence of hyperkalemia, for example, the ALDO antagonist component, typically spironolactone, will be present in the combination therapy in an amount in a range from about 1 mg to about 25 mg per dose. A preferred range
10 for spiro lactone would be from about 5 mg to 15 mg per dose. More preferably would be a range from about 10 mg to 15 mg per dose per day.

Examples of various fixed combinations of ACE
15 inhibitor and ALDO antagonist representing a "double therapy" of the invention are as follow:

	<u>ACE Inhibitor</u>		<u>ALDO Antagonist</u>
	Captopril (mg) ¹	Enalapril (mg) ²	Spironolactone (mg) ²
20	12.5 to 25	5 to 15	5
	12.5 to 25	5 to 15	7.5
	12.5 to 25	5 to 15	10
	12.5 to 25	5 to 15	12.5
	12.5 to 25	5 to 15	15
25	12.5 to 25	5 to 15	17.5
	12.5 to 25	5 to 15	20
	12.5 to 25	5 to 15	22.5

¹Dose given 1, 2 or 3 times per day

30 ²Dose given once per day

The active ingredients may also be administered by injection as a composition wherein, for example, saline, 35 dextrose or water may be used as a suitable carrier.

The dosage regimen for treating a disease condition with the combination therapy of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex and medical condition of the 5 patient, the severity of the disease, the route of administration, and the particular compound employed, and thus may vary widely.

For therapeutic purposes, the active components 10 of this combination therapy invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the components may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl 15 esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration.

Such capsules or tablets may contain a controlled-release 20 formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or 25 suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The components may be dissolved in water, polyethylene glycol, propylene glycol, 30 ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

35 Pharmaceutical compositions for use in the treatment methods of the invention may be administered in oral form or by intravenous administration. Oral

administration of the combination therapy is preferred. Dosing for oral administration may be with a regimen calling for single daily dose, or for a single dose every other day, or for multiple, spaced doses throughout the 5 day. The active agents which make up the combination therapy may be administered simultaneously, either in a combined dosage form or in separate dosage forms intended for substantially simultaneous oral administration. The active agents which make up the combination therapy may 10 also be administered sequentially, with either active component being administered by a regimen calling for two-step ingestion. Thus, a regimen may call for sequential administration of the active agents with spaced-apart ingestion of the separate, active agents. The time period 15 between the multiple ingestion steps may range from a few minutes to several hours, depending upon the properties of each active agent such as potency, solubility, bioavailability, plasma half-life and kinetic profile of the agent, as well as depending upon the age and condition 20 of the patient. The active agents of the combined therapy whether administered simultaneously, substantially simultaneously, or sequentially, may involve a regimen calling for administration of one active agent by oral route and the other active agent by intravenous route. 25 Whether the active agents of the combined therapy are administered by oral or intravenous route, separately or together, each such active agent will be contained in a suitable pharmaceutical formulation of pharmaceutically-acceptable excipients, diluents or other formulations 30 components. Examples of suitable pharmaceutically-acceptable formulations containing the active components for oral administration are given below. Even though such formulations list both active agents together in the same recipe, it is appropriate for such recipe to be utilized 35 for a formulation containing one of the active components.

Example 1

An oral dosage may be prepared by screening and then mixing together the following list of ingredients in the 5 amounts indicated. The dosage may then be placed in a hard gelatin capsule.

	<u>Ingredients</u>	<u>Amounts</u>
10	captopril	62.0 mg
	spironolactone	12.5 mg
	magnesium stearate	10 mg
	lactose	100 mg

Example 2

15 An oral dosage may be prepared by mixing together granulating with a 10% gelatin solution. The wet granules are screened, dried, mixed with starch, talc and stearic acid, screened and compressed into a tablet.

	<u>Ingredients</u>	<u>Amounts</u>
20	captopril	62.0 mg
	spironolactone	12.5 mg
	calcium sulfate dihydrate	100 mg
25	sucrose	15 mg
	starch	8 mg
	talc	4 mg
	stearic acid	2 mg

Example 3

An oral dosage may be prepared by screening and then mixing together the following list of ingredients in the 5 amounts indicated. The dosage may then be placed in a hard gelatin capsule.

	<u>Ingredients</u>	<u>Amounts</u>
10	enalapril	14.3 mg
	spironolactone	12.5 mg
	magnesium stearate	10 mg
	lactose	100 mg

15 Example 4

An oral dosage may be prepared by mixing together granulating with a 10% gelatin solution. The wet granules are screened, dried, mixed with starch, talc and stearic 20 acid, screened and compressed into a tablet.

	<u>Ingredients</u>	<u>Amounts</u>
25	enalapril	14.3 mg
	spironolactone	12.5 mg
	calcium sulfate dihydrate	100 mg
	sucrose	15 mg
	starch	8 mg
	talc	4 mg
30	stearic acid	2 mg

Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations.

What Is Claimed Is:

1. A combination comprising a therapeutically-effective amount of an angiotensin converting enzyme inhibitor and an aldosterone receptor antagonist, said aldosterone receptor antagonist being present in an amount which is therapeutically effective to antagonize a physiological effect of aldosterone but which amount is not sufficient for said aldosterone receptor antagonist to cause a substantial diuretic effect.

2. The combination of Claim 1 wherein said aldosterone receptor antagonist is a spirolactone-type compound.

15 3. The combination of Claim 2 wherein said spirolactone-type compound is spironolactone.

4. The combination of Claim 1 wherein
20 angiotensin converting enzyme inhibitor is selected from the group consisting of alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, saralasin acetate, temocapril, trandolapril, ceranapril, moexipril, quinaprilat, spirapril, Bioproject BP1.137, Chiesi CHF 1514, Fisons FPL-66564, idrapril, Marion Merrell Dow MDL-100240, perindoprilat and Servier S-5590.

30 5. The combination of Claim 4 wherein said angiotensin converting enzyme inhibitor is selected from the group consisting of alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, saralasin acetate, temocapril, trandolapril, ceranapril, moexipril, quinaprilat and spirapril.

6. The combination of Claim 1 further characterized by said angiotensin converting enzyme inhibitor and said aldosterone receptor antagonist being present in said combination in a weight ratio range from 5 about 0.1-to-one to about twenty-five-to-one of said angiotensin converting enzyme inhibitor to said aldosterone receptor antagonist.

7. The combination of Claim 6 wherein said 10 weight ratio range is from about 0.5-to-one to about fifteen-to-one.

8. The combination of Claim 7 wherein said weight ratio range is from about 0.5-to-one to about five-15 to-one.

9. A co-therapy for treating a cardiovascular disorder in a subject afflicted with or susceptible to multiple cardiovascular disorders, wherein said co-therapy 20 comprises administering a therapeutically-effective amount of an angiotensin converting enzyme inhibitor and administering an aldosterone receptor antagonist in an amount therapeutically effective to antagonize aldosterone but insufficient to cause substantial diuretic effect.

25

10. The co-therapy of Claim 9 wherein said subject is afflicted with or susceptible to hypertension and said subject further requires avoidance of the incidence of hyperkalemia.

30

11. The co-therapy of Claim 10 wherein said subject is further susceptible to congestive heart failure.

12. The co-therapy of Claim 10 wherein said 35 subject is further susceptible to ventricular hypertrophy.

13. The co-therapy of Claim 10 further characterized by administering said angiotensin converting enzyme inhibitor and said aldosterone receptor antagonist in a sequential manner.

5

14. The co-therapy of Claim 10 further characterized by administering said angiotensin converting enzyme inhibitor and said aldosterone receptor antagonist in a substantially simultaneous manner.

10

15. The co-therapy of Claim 9 wherein said aldosterone receptor antagonist is a spirolactone-type compound.

15

16. The co-therapy of Claim 15 wherein said spirolactone-type compound is spironolactone.

20

17. The co-therapy of Claim 9 wherein said amgiotensin converting enzyme inhibitor is selected from the group consisting of alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, saralasin acetate, temocapril, trandolapril, ceranapril, moexipril, quinaprilat, spirapril, Bioproject BP1.137, Chiesi CHF 1514, Fisons FPL-66564, idrapril, Marion Merrell Dow MDL-100240, perindoprilat and Servier S-5590.

25

18. The co-therapy of Claim 17 wherein said angiotensin converting enzyme inhibitor is selected from the group consisting of alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, saralasin acetate, temocapril, trandolapril, ceranapril, moexipril, quinaprilat and spirapril.

19. The co-therapy of Claim 9 further characterized by said angiotensin converting enzyme inhibitor and said aldosterone receptor antagonist being used in said co-therapy in a weight ratio range from about 5 0.1-to-one to about twenty-five-to-one of said angiotensin converting enzyme inhibitor to said aldosterone receptor antagonist.

20. The co-therapy of Claim 19 wherein said 10 weight ratio range is from about 0.5-to-one to about fifteen-to-one.

21. The co-therapy of Claim 20 wherein said weight ratio range is from about 0.5-to-one to about five-15 to-one.

22. The co-therapy of Claim 9 wherein said angiotensin converting enzyme inhibitor is captopril, in a daily dose range from about 30 mg to about 80 mg per dose, 20 or is enalapril in a dose range from about 5 mg to about 25 mg per dose.

23. The co-therapy of Claim 22 wherein said aldosterone receptor antagonist is spironolactone in a 25 daily dose range from about 1 mg to about 23 mg per dose.

24. The co-therapy of Claim 23 wherein said spironolactone daily dose is in a range from about 5 mg to about 20 mg.
30

25. The co-therapy of Claim 23 wherein said spironolactone daily dose is in a range from about 5 mg to about 15 mg.

26. A pharmaceutically-acceptable dosage form comprising one or more excipients and a fixed combination consisting of two cardiovascular drug components, wherein
5 said first drug component is an ACE inhibitor and said second component is spironolactone, wherein said first and second components are present in the dosage form in a weight ratio of said-first-component-to-said-component in a range from about 0.1-to-one to about 25-to-one.

10

27. The dosage form of Claim 26 wherein said weight ratio range is 0.5-to-one to about 15-to-one.

28. The dosage form of Claim 27 wherein said ACE
15 inhibitor is selected from the group consisting of alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, saralasin acetate, temocapril, trandolapril, ceranapril,
20 moexipril, quinaprilat and spirapril.


29. The dosage form of Claim 28 wherein said ACE inhibitor is enalapril.

25 30. The dosage form of Claim 29 wherein enalapril is present in an amount selected from a range from about 5 mg to about 20 mg and spironolactone is present in an amount selected from a range from about 5 mg to about 22.5 mg.

30


1 / 5

FIG. I




2 / 5

FIG. 2




3 / 5

FIG. 3



4 / 5

FIG. 4



5 / 5

FIG. 5

